Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients

Summary

Study to obtain information about the safety and tolerability of tiotropium bromide administered via the Respimat® inhalation device in pediatric (≤11 y.o.) and adolescent/adult (≥12 y.o.) cystic fibrosis (CF) patients after single and multiple doses as well as to obtain pharmacokinetic data for tiotropium in CF patients after single and multiple doses

Timeline

Start

2006-09

Primary completion

2008-09

Completion

—

Drugs

Indications